Literature DB >> 28511255

Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Maria Eliza Freitas1, Christopher W Hess2, Susan H Fox1.   

Abstract

Motor complications are a consequence of the chronic treatment of Parkinson's disease (PD) and include motor fluctuations (wearing-off phenomenon) and levodopa-induced dyskinesia. Both can have a significant impact on functionality and quality of life; thus, proper recognition and management is essential. The phenomenology and temporal relationship of motor complications to the schedule of levodopa dosing can be helpful in characterizing them. There are several therapeutic approaches to motor complications, including pharmacological and surgical options. The authors summarize the different types of motor complications according to phenomenology and the currently available medical treatments, including ongoing trials for the management of this condition.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28511255      PMCID: PMC5990008          DOI: 10.1055/s-0037-1602423

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  99 in total

Review 1.  Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

Authors:  Rebecca Stowe; Natalie Ives; Carl E Clarke; Katherine Deane; Keith Wheatley; Richard Gray; Kelly Handley; Alex Furmston
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

Review 2.  Treating the Motor Symptoms of Parkinson Disease.

Authors:  John C Morgan; Susan H Fox
Journal:  Continuum (Minneap Minn)       Date:  2016-08

3.  Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Authors:  Rupam Borgohain; Jozsef Szasz; Paolo Stanzione; Chandrashekhar Meshram; Mohit H Bhatt; Dana Chirilineau; Fabrizio Stocchi; Valentina Lucini; Rodolfo Giuliani; Emma Forrest; Patricia Rice; Ravi Anand
Journal:  Mov Disord       Date:  2014-07-10       Impact factor: 10.338

4.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

Authors:  R B Dewey; J T Hutton; P A LeWitt; S A Factor
Journal:  Arch Neurol       Date:  2001-09

Review 5.  Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.

Authors:  Joseph Jankovic
Journal:  Mov Disord       Date:  2005       Impact factor: 10.338

Review 6.  Pharmacokinetics of levodopa.

Authors:  Manuela Contin; Paolo Martinelli
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

Review 7.  Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.

Authors:  Santiago Perez-Lloret; María Verónica Rey; James Crispo; Daniel Krewski; Marise Lapeyre-Mestre; Jean-Louis Montastruc; Olivier Rascol
Journal:  Expert Opin Drug Saf       Date:  2014-03       Impact factor: 4.250

Review 8.  Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.

Authors:  Karin Wirdefeldt; Per Odin; Dag Nyholm
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

9.  Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial.

Authors:  Alessandra Nicoletti; Gennarina Arabia; Pierfrancesco Pugliese; Giuseppe Nicoletti; Giusi Torchia; Francesca Condino; Letterio Morgante; Aldo Quattrone; Mario Zappia
Journal:  Clin Neuropharmacol       Date:  2007 Sep-Oct       Impact factor: 1.592

10.  Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Authors:  Per Svenningsson; Carl Rosenblad; Karolina Af Edholm Arvidsson; Klas Wictorin; Charlotte Keywood; Bavani Shankar; David A Lowe; Anders Björklund; Håkan Widner
Journal:  Brain       Date:  2015-02-10       Impact factor: 13.501

View more
  17 in total

1.  Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Elaine Bandeira Cavalcanti Duarte; Laura Maria Ramos Miranda; Andore Guescel C Asano; Nadja Maria Jorge Asano; Maria de Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Neuromolecular Med       Date:  2019-05-22       Impact factor: 3.843

2.  Rotigotine Transdermal Patch: A Review in Parkinson's Disease.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2019-07       Impact factor: 5.749

3.  Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.

Authors:  Meliha Güneş; Sinem Yaprak Karavana
Journal:  Turk J Pharm Sci       Date:  2022-06-27

4.  Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.

Authors:  Bruno Bergmans; Philip Bourgeois; Patrick Cras; Sophie Dethy; Nina De Klippel; Gianni Franco; Gaëtan Garraux; Karine Geens; Philippe Jacquerye; Anne Jeanjean; Frédéric Supiot; Chris Van der Linden; Claude Krygier
Journal:  Acta Neurol Belg       Date:  2022-10-06       Impact factor: 2.471

5.  Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Isaura Isabelle Fonseca Gomes da Silva; Amdore Guescel C Asano; Nadja Maria Jorge Asano; Maria De Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Mol Biol Rep       Date:  2020-11-05       Impact factor: 2.316

Review 6.  Parkinson's disease: Are gut microbes involved?

Authors:  Yogesh Bhattarai; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-09-02       Impact factor: 4.052

Review 7.  A Stage-Based Approach to Therapy in Parkinson's Disease.

Authors:  Claudia Carrarini; Mirella Russo; Fedele Dono; Martina Di Pietro; Marianna G Rispoli; Vincenzo Di Stefano; Laura Ferri; Filomena Barbone; Michela Vitale; Astrid Thomas; Stefano Luca Sensi; Marco Onofrj; Laura Bonanni
Journal:  Biomolecules       Date:  2019-08-20

8.  Continuous home monitoring of Parkinson's disease using inertial sensors: A systematic review.

Authors:  Marco Sica; Salvatore Tedesco; Colum Crowe; Lorna Kenny; Kevin Moore; Suzanne Timmons; John Barton; Brendan O'Flynn; Dimitrios-Sokratis Komaris
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

9.  Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.

Authors:  Andrew Thach; Eddie Jones; Eric Pappert; James Pike; Jack Wright; Alexander Gillespie
Journal:  BMC Neurol       Date:  2021-01-30       Impact factor: 2.474

10.  Neuroprotective Activities of Crossyne flava Bulbs and Amaryllidaceae Alkaloids: Implications for Parkinson's Disease.

Authors:  Sylvester I Omoruyi; Abobaker S Ibrakaw; Okobi E Ekpo; James S Boatwright; Christopher N Cupido; Ahmed A Hussein
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.